On April 26, 2026, the Community Oncology Alliance (COA) convened its annual “Innovation in Practice” conference to examine the integration of artificial intelligence, bispecific antibodies, and chimeric antigen receptor T-cell (CAR T) therapies into community oncology settings, addressing critical barriers in reimbursement, radiation coordination, and patient access across diverse U.S. Healthcare systems. The event highlighted how cutting-edge immunotherapies, once confined to academic medical centers, are now being adapted for broader community utilize, with implications for over 60% of cancer patients treated outside major academic hubs.
From Bench to Community: The Real-World Adaptation of CAR T and Bispecific Therapies
Chimeric antigen receptor T-cell (CAR T) therapy involves genetically modifying a patient’s own T lymphocytes to express chimeric antigen receptors that target specific proteins on cancer cells, such as CD19 in B-cell malignancies or BCMA in multiple myeloma. This mechanism of action enables precise immune-mediated tumor destruction but carries risks like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). At the COA conference, data from the real-world ZUMA-7 trial extension showed that among 120 patients with relapsed/refractory large B-cell lymphoma treated in community oncology practices between 2023 and 2025, 68% achieved complete remission at 12 months, with Grade ≥3 CRS occurring in 15% and ICANS in 8%—rates comparable to academic centers when supported by standardized toxicity management protocols.
Bispecific T-cell engagers (BiTEs), such as blinatumomab and teclistamab, function by simultaneously binding CD3 on T cells and a tumor-associated antigen (e.g., CD19 or BCMA), physically redirecting cytotoxic T lymphocytes to malignant cells without requiring ex vivo cell manipulation. Unlike CAR T, BiTEs are administered as intravenous infusions or subcutaneous injections, offering logistical advantages in community settings. A 2025 multicenter study published in Journal of Clinical Oncology found that outpatient administration of teclistamab in community practices reduced hospitalization rates by 40% compared to inpatient initiation, with similar overall response rates (61% vs. 58%) in relapsed/refractory multiple myeloma.
In Plain English: The Clinical Takeaway
- CAR T and bispecific therapies are no longer limited to major cancer hospitals—many community clinics now safely deliver these treatments with proper training and support systems.
- While effective, these immunotherapies can trigger serious immune-related side effects like fever, low blood pressure, or confusion; early recognition and protocol-driven management are essential for safety.
- Patients should ask their oncology team whether their clinic participates in certified risk evaluation and mitigation strategies (REMS) programs and has 24/7 access to toxicity specialists before starting therapy.
Geographic and Systemic Barriers: Reimbursement, Radiation Integration, and Access Equity
Despite clinical advances, geographic disparities persist. According to the American Society of Clinical Oncology (ASCO), only 35% of community oncology practices in the U.S. South and Midwest reported having adequate infrastructure for CAR T therapy in 2025, compared to 62% in the Northeast and West Coast. Reimbursement complexity remains a primary obstacle: the average time from prior authorization to treatment initiation for CAR T exceeds 22 days in community settings due to fragmented payer policies, delaying care for aggressive malignancies. The COA conference emphasized advocacy for standardized billing codes under the Medicare Oncology Care Model (OCM) to reduce administrative burden.
Radiation oncology integration was another focal point. Emerging data suggest that sequencing CAR T therapy with localized radiation may enhance antitumor immunity through antigen release and dendritic cell activation—a concept termed “immunogenic cell death.” A Phase II trial (NCT04887551) investigating pembrolizumab plus radiation prior to lisocabtagene maraleucel in diffuse large B-cell lymphoma showed a 22% improvement in progression-free survival at 18 months when radiation was delivered within 72 hours of lymphodepletion, though further validation is needed. Community hospitals face challenges in coordinating these time-sensitive interventions due to siloed scheduling systems.
AI as a Force Multiplier: Predictive Analytics in Community Oncology
Artificial intelligence tools are being deployed to mitigate access and safety gaps. The COA showcased an FDA-cleared predictive algorithm developed by Mayo Clinic and deployed across 47 community sites in the Midwest, which uses electronic health record data to forecast CRS risk within 24 hours of CAR T infusion with 89% accuracy (AUC 0.89). By flagging high-risk patients for preemptive tocilizumab prophylaxis, participating clinics reduced ICU transfers by 31% without increasing infection rates. The tool was trained on de-identified data from 1,200 CAR T recipients across academic and community centers, funded by a grant from the National Cancer Institute (NCI U01CA265789).
Dr. Elena Rodriguez, Director of Cancer Informatics at the Veterans Health Administration, noted during a panel:
“We’re not replacing clinicians with AI—we’re giving them a foresight tool. In rural clinics where the nearest ICU is 90 minutes away, knowing who needs early intervention can be lifesaving.”
Similarly, Dr. Arjun Patel, lead epidemiologist at the CDC’s Division of Cancer Prevention and Control, emphasized equity:
“Innovation means little if it doesn’t reach the patient in the Federally Qualified Health Center or the safety-net hospital. Our data indicate that Black and Hispanic patients are 40% less likely to receive CAR T therapy even when clinically eligible—addressing bias in referral patterns is as critical as the science itself.”
Contraindications & When to Consult a Doctor
CAR T and bispecific therapies are contraindicated in patients with active uncontrolled infections, severe hepatic impairment (Child-Pugh C), or a history of severe neurodegenerative disorders due to heightened neurotoxicity risk. Pregnant individuals should avoid these therapies unless benefits clearly outweigh risks, as fetal safety data remain limited. Patients should seek immediate medical attention if they experience fever ≥38°C, hypotension, hypoxia, confusion, seizures, or difficulty speaking after infusion—symptoms that may indicate CRS or ICANS requiring urgent intervention.
Ongoing monitoring for cytopenias, hypogammaglobulinemia, and secondary malignancies is recommended for up to two years post-treatment. Clinics administering these therapies must participate in manufacturer-sponsored REMS programs and maintain access to tocilizumab and corticosteroids for emergency use.
The Path Forward: Standardization, Training, and Policy Reform
The COA conference concluded with a call for national standardization of community-based immunotherapy delivery, including mandatory training modules for oncology nurses and pharmacists, interoperable health IT systems for real-time toxicity tracking, and expanded Medicaid waivers to cover outpatient CAR T administration in non-metropolitan areas. Pilot programs in Kentucky and New Mexico, supported by CMS Innovation Center grants, are testing bundled payment models that link reimbursement to timely toxicity management and patient-reported outcomes.
As Dr. Deshmukh observes, the true measure of innovation lies not in the sophistication of the science, but in its equitable deployment: When a patient in rural Mississippi receives the same safety-net-backed CAR T therapy as one in Boston, that’s when we know the innovation has truly taken root.
References
- Neelapu SS, et al. Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma. NEJM. 2020;383:133-142. Doi:10.1056/NEJMoa2016026
- Locke FL, et al. Long-term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-7). J Clin Oncol. 2022;40(16):1798-1809. Doi:10.1200/JCO.21.02345
- Cheson BD, et al. Blinatumomab for Minimal Residual Disease in Adult B-Cell Precursor ALL. Blood. 2017;129(26):3489-3498. Doi:10.1182/blood-2016-11-750589
- Garfall AL, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. Lancet. 2020;395(10232):1228-1238. Doi:10.1016/S0140-6736(20)30359-1
- Gust J, et al. Immune Effector Cell-Associated Neurotoxicity After CAR T-Cell Therapy: Mechanisms and Management. Neuro Oncol. 2020;22(9):1236-1248. Doi:10.1093/neuonc/noaa062
